Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy

Abstract Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy. Indeed, modulating immune inhibitory pathways has been consid...

Full description

Bibliographic Details
Main Authors: Roberta Mazzone, Clemens Zwergel, Antonello Mai, Sergio Valente
Format: Article
Language:English
Published: BMC 2017-05-01
Series:Clinical Epigenetics
Subjects:
Cancer
Epigenetics
Immunotherapy
HDAC inhibitors
DNA methylation
Immune checkpoint inhibitors
Online Access:http://link.springer.com/article/10.1186/s13148-017-0358-y

Internet

http://link.springer.com/article/10.1186/s13148-017-0358-y

Similar Items